GlassScriptPhysician profile
Michaela A Dean
NPI 1225711856
$1,509.47
in general payments reported to CMS, 2019-2025
35 companies · $941 in 2025
The $941 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $88.02 · 2024: $481 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.50 |
| Education | $265.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $239.19 | 2024 | |
| Daiichi Sankyo INC. | $152.36 | 2024-2025 | Enhertu, Vanflyta |
| Seagen INC. | $99.99 | 2025 | |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $81.29 | 2025 | |
| Janssen Biotech, INC. | $73.66 | 2025 | Rybrevant, Carvykti |
| Beone Medicines USA, INC. | $72.11 | 2025 | Tevimbra, Brukinsa |
| Genentech USA, INC. | $67.74 | 2024-2025 | Polivy, Venclexta, Lunsumio |
| Servier Pharmaceuticals LLC | $66.22 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $43.65 | 2024-2025 | Onivyde |
| Abbvie INC. | $36.91 | 2024-2025 | |
| Organon LLC | $36.27 | 2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $36.05 | 2025 | Keytruda, Welireg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.89 | 2023 | Jardiance |
| Astellas Pharma US INC | $29.89 | 2025 | Vyloy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $25.85 | 2025 | Epkinly |
| Astrazeneca Pharmaceuticals LP | $22.97 | 2024 | Tagrisso |
| Novo Nordisk INC | $21.63 | 2024 | Rybelsus, Ozempic |
| Kite Pharma, INC. | $20.86 | 2024 | Yescarta |
| Incyte Corporation | $18.94 | 2024 | Jakafi |
| Rigel Pharmaceuticals, INC. | $18.84 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Jazz Pharmaceuticals INC. | $18.26 | 2025 | |
| Eisai INC. | $17.26 | 2025 | |
| Glaxosmithkline, LLC. | $17.22 | 2025 | Zejula, Jemperli |
| Exelixis INC. | $16.13 | 2025 | Cabometyx |
| Pfizer INC. | $15.87 | 2025 | |
| Exact Sciences Corporation | $15.86 | 2023 | Cologuard Collection Kit |
| Aveo Pharmaceuticals, INC. | $15.82 | 2025 | |
| Geron Corporation | $15.53 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $15.28 | 2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $14.70 | 2025 | Iclusig |
| Lilly USA, LLC | $14.70 | 2025 | Verzenio, Jaypirca |
| Alexion Pharmaceuticals, INC. | $14.24 | 2025 | Ultomiris |
| Pharmaand Gmbh | $14.15 | 2025 | Rubraca |
| Tolmar, INC. | $14.15 | 2025 | Eligard, Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.